Amgen Inc. has an expansion plan and China is a part of it. On 31 October, the major US biotech announced the acquisition of a 20.5% stake in Beijing-based BeiGene Ltd. for $2.7bn in cash, paying a 36% premium over Nasdaq-listed BeiGene’s 30-day volume-weighted share price.
As part of the transaction, BeiGene will commercialize three Amgen products in China including Xgeva/Prolia (denosumab), which is already approved...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

